Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor

Ji,Xiaojian; Ji,Yan; Wang,Wenqing; Xu,Xinmei

doi:10.3892/ol.2018.8210

Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor

Authors:
- Xiaojian Ji
- Yan Ji
- Wenqing Wang
- Xinmei Xu
View Affiliations

Affiliations: Emergency Department, The People's Hospital of Guizhou Province, Guiyang, Guizhou 550002, P.R. China, Department of Hematology and Oncology, Regions Hospital, St. Paul, MN 55101, USA
Published online on: March 8, 2018 https://doi.org/10.3892/ol.2018.8210
Pages: 7221-7230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Forkhead box N1 (FOXN1) belongs to the FOX family of transcription factors, which comprises a diverse group of winged-helix proteins. FOXN1 is a ubiquitously expressed member that has been implicated in the embryo development, metabolism, aging and cancer. However, little is known regarding the role of FOXN1 in non‑small cell lung cancer (NSCLC). The aim of the study was to investigate the function of FOXN1 in NSCLC and examine the relevant mechanism. In the present study, using reverse transcription‑quantitative polymerase chain reaction, western blotting, transwell assay, MTT assay, luciferase report assy, it was identified that knockdown of FOXN1 increased the proliferation of A549 and H1299 cells, while overexpression of FOXN1 evidently suppressed the cell growth. A Transwell assay was used to determine the relative cell invasion ability, and it was observed that the invading cells were markedly decreased in the FOXN1 overexpression groups; by contrast, reduced expression of FOXN1 demonstrated the potential to promote cell invasion. Furthermore, lower expression of FOXN1 was observed in NSCLC tissues and cell lines as compared with the adjacent non‑tumor tissues or human bronchial epithelial cells, respectively. A higher level of FOXN1 was associated with a better prognosis of NSCLC patients. Quantitative chromatin immunoprecipitation analysis and luciferase reporter gene assays revealed that enhancer of zeste homolog 2 (EZH2) and β‑catenin were two target genes of FOXN1. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis indicated that FOXN1 suppressed the expression levels of these target genes at the transcriptional level. In conclusion, the present study demonstrated that FOXN1 served major roles in NSCLC proliferation and invasion by directly repressing EZH2 and β‑catenin, which suggested that FOXN1 may function as a tumor suppressor in NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Van Z, Wijk N and Fong KM: Update in lung cancer: Prologue to a modern review series. Respirology. 20:183–184. 2015. View Article : Google Scholar : PubMed/NCBI
3	O'Dowd EL and Baldwin DR: Early diagnosis pivotal to survival in lung cancer. Practitioner. 258(21–24): 2–3. 2014.
4	Sharma SP: New therapeutic target for non-small-cell lung cancer. Lancet Oncol. 15:e5332014. View Article : Google Scholar : PubMed/NCBI
5	Yang T, Li H, Thakur A, Chen T, Xue J, Li D and Chen M: FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells. Tumour Biol. 36:8185–8191. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cuiffo BG and Karnoub AE: Silencing FOXP2 in breast cancer cells promotes cancer stem cell traits and metastasis. Mol Cell Oncol. 3:e10190222015. View Article : Google Scholar : PubMed/NCBI
7	Feng J, Zhang X, Zhu H, Wang X, Ni S and Huang J: High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 138:230–235. 2012. View Article : Google Scholar : PubMed/NCBI
8	Liu H, Li W, Yu X, Gao F, Duan Z, Ma X, Tan S, Yuan Y, Liu L, Wang J, et al: EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Oncotarget. 7:56338–56354. 2016.PubMed/NCBI
9	Jin J, Zhan P, Katoh M, Kobayashi SS, Phan K, Qian H, Li H, Wang X, Wang X and Song Y: written on behalf of the AME Lung Cancer Collaborative Group: Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: A meta-analysis. Transl Lung Cancer Res. 6:97–108. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zell JA, Ou Ignatius SH, Ziogas A and Anton-Culver H: Validation of the proposed International Association for the Study of Lung Cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry. J Thorac Oncol. 2:1078–1085. 2007. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Palamaro L, Romano R, Fusco A, Giardino G, Gallo V and Pignata C: FOXN1 in organ development and human diseases. Int Rev Immunol. 33:83–93. 2014. View Article : Google Scholar : PubMed/NCBI
13	Mittal V: Epithelial mesenchymal transition in aggressive lung cancers. Adv Exp Med Biol. 890:37–56. 2016. View Article : Google Scholar : PubMed/NCBI
14	Xu C, Hou Z, Zhan P, Zhao W, Chang C, Zou J, Hu H, Zhang Y, Yao X, Yu L and Yan J: EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med Oncol. 30:7132013. View Article : Google Scholar : PubMed/NCBI
15	Geng J, Li X, Zhou Z, Wu CL, Dai M and Bai X: EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett. 359:275–287. 2015. View Article : Google Scholar : PubMed/NCBI
16	Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, et al: EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 19:6556–6565. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhou W, Wang J, Man WY, Zhang QW and Xu WG: siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Asian Pac J Cancer Prev. 16:2425–2430. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zhu Z, Tang J, Wang J, Duan G, Zhou L and Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
19	Zhang HJ, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, et al: MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem. 31:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J and Huang H: LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 6:41045–41055. 2015. View Article : Google Scholar : PubMed/NCBI
21	Kim Y, Jin D, Lee BB, Cho EY, Han J, Shim YM, Kim HK and Kim DH: Overexpression of β-catenin and cyclin D1 is associated with poor overall survival in patients with stage IA-IIA squamous cell lung cancer irrespective of adjuvant chemotherapy. J Thorac Oncol. 11:2193–2201. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wang Z, Luo Z, Zhou L, Li X, Jiang T and Fu E: DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway. Cancer Sci. 106:1303–1312. 2015. View Article : Google Scholar : PubMed/NCBI
23	Chen CC, Chen HY, Su KY, Hong QS, Yan BS, Chen CH, Pan SH, Chang YL, Wang CJ, Hung PF, et al: Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer. Am J Respir Crit Care Med. 190:433–444. 2014. View Article : Google Scholar : PubMed/NCBI
24	Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI
25	Tseng RC, Lin RK, Wen CK, Tseng C, Hsu HS, Hsu WH and Wang YC: Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene. 27:4488–4496. 2008. View Article : Google Scholar : PubMed/NCBI